Chronic Renal Failure
Conditions
Keywords
Calcium Dobesilate, Non Dialysis Patients With CKD(3-5), Glomerular filtration rate, serum creatinine
Brief summary
To investigate the feasibility of calcium dobesilate in the treatment of microvascular injury provides new ideas and theoretical basis for the prevention and treatment of chronic renal failure.
Detailed description
The deterioration of renal function is closely related to microvascular damage, calcium dobesilate is known as microcirculation protective agent, the investigators will further study its effect of non dialysis patients with chronic renal failure and explore the feasibility of calcium dobesilate in treatment of renal microvascular injury, the investigators will provide new ideas and theoretical basis for the prevention and treatment of chronic renal failure.
Interventions
DRUGCalcium Dobesilate group
Calcium dobesilate was used to treat patients with chronic renal failure on the basis of conventional treatment.
Conventional treatment were used to treat patients with chronic renal failure.
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Enroll the non dialysis patients with chronic renal failure hospitalized in the Department of Nephrology of the Affiliated Hospital of Xuzhou Medical University. * According to the glomerular filtration rate, the patients who were not required to be dialysate were at CKD3-5 (GFR between 10 and 59ml/min).
Exclusion criteria
* Exclude those patients with diabetes, cardiovascular disease, severe infection, shock, dehydration, abnormal liver function, received glucocorticoid therapy, surgery and emergency dialysis. * Eliminate those patients with respiratory disease(such as chronic obstructive pulmonary disease, bronchiectasis, asthma), cardiovascular diseases(such as acute and chronic cardiac insufficiency), blood system diseases (such as aplastic anemia, nutritional anemia and polycythemia vera).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| glomerular filtration rate | up to 6 months | emission computed tomography |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| serum creatinine | up to 6 months | intravenous blood sampling |
| Cystatin C | up to 6 months | intravenous blood sampling |
Countries
China
Contacts
Primary ContactDong Sun, MD
Outcome results
None listed